Evidence map›Paper›PMID 12764552›Full record

ReviewEuropean journal of nuclear medicine and molecular imaging2003

PET-based molecular imaging in neuroscience.

A H Jacobs, H Li, A Winkeler, R Hilker, C Knoess, A Rüger, N Galldiks, B Schaller, J Sobesky, L Kracht and 9 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in European journal of nuclear medicine and molecular imaging, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 97 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. PET molecular imaging for pathophysiological visualization in Alzheimer's disease.European journal of nuclear medicine and molecular imaging · 2023
    Review
  6. Reporter Genes for Brain Imaging Using MRI, SPECT and PET.International journal of molecular sciences · 2022
    Review
  7. Review
  8. Article
  9. Transpathology: molecular imaging-based pathology.European journal of nuclear medicine and molecular imaging · 2021
    Review
  10. Review
  11. Imaging in vivo glutamate fluctuations with [(11)C]ABP688: a GLT-1 challenge with ceftriaxone.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2015
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Role of small animal PET for molecular imaging in pre-clinical studies.European journal of nuclear medicine and molecular imaging · 2007
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

A H JacobsLaboratory for Gene Therapy and Molecular Imaging, Max-Planck-Institute for Neurological Research, Gleuelerstrasse 50, 50931, Cologne, Germany. Andreas.Jacobs@pet.mpin-koeln.mpg.de
H Li
A Winkeler
R Hilker
C Knoess
A Rüger
N Galldiks
B Schaller
J Sobesky
L Kracht
P Monfared
M Klein
S Vollmar
B Bauer
R Wagner
R Graf
K Wienhard
K Herholz
W D Heiss
Max Planck Institute for Metabolism Research · DEUniversity of Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Positron emission tomography (PET) allows non-invasive assessment of physiological, metabolic and molecular processes in humans and animals in vivo. Advances in detector technology have led to a considerable improvement in the spatial resolution of PET (1-2 mm), enabling for the first time investigations in small experimental animals such as mice. With the developments in radiochemistry and tracer technology, a variety of endogenously expressed and exogenously introduced genes can be analysed by PET. This opens up the exciting and rapidly evolving field of molecular imaging, aiming at the non-invasive localisation of a biological process of interest in normal and diseased cells in animal models and humans in vivo. The main and most intriguing advantage of molecular imaging is the kinetic analysis of a given molecular event in the same experimental subject over time. This will allow non-invasive characterisation and "phenotyping" of animal models of human disease at various disease stages, under certain pathophysiological stimuli and after therapeutic intervention. The potential broad applications of imaging molecular events in vivo lie in the study of cell biology, biochemistry, gene/protein function and regulation, signal transduction, transcriptional regulation and characterisation of transgenic animals. Most importantly, molecular imaging will have great implications for the identification of potential molecular therapeutic targets, in the development of new treatment strategies, and in their successful implementation into clinical application. Here, the potential impact of molecular imaging by PET in applications in neuroscience research with a special focus on neurodegeneration and neuro-oncology is reviewed.

Indexed as

Gene Expression RegulationAlzheimer DiseaseAnimalsBrainBrain NeoplasmsGliomaHumansNeurosciencesParkinson DiseaseProteinsProtein TransportRadiopharmaceuticalsTomography, Emission-ComputedProteinsRadiopharmaceuticals

Identifiers

PMID12764552
OpenAlexW2069229423

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.